Mowbi

As we all wind down 2024 it’s not just our musical choices that have us reflecting. It’s the perfect time to take stock of the year behind us, and what a year it’s been for Mowbi! We kicked off 2024 with our updated Scrappy Marketing guide, then dove right into events season (connecting with so many of you has truly been a highlight!), treated your ears to some communication gems in season 3 of our Pros and Comms podcast and topped it all off as OBN award finalists! Thank you to everyone we’ve met this year, 2025 is already promising to be an amazing one! #mowbi #wrapup #2025 #reflection #marketing

Last weeks GIANT Health Event bought together hundreds of people from the NHS and wider healthcare sphere to create an inspiring 2 days of panel sessions, presentations and start-up pitches. On Monday, we joined Discovery Park as they hosted the Innovation, Investment and Impact show, here are a few of Mowbi’s highlights 👇 💡To demonstrate value to different stakeholders you need to have conviction and confidence in your idea but be flexible to feedback. You need to be very clear, concise, and transparent about your story to communicate that value effectively to various stakeholders “Transitioning from Healthcare & Life Sciences to the commercial ecosystem” Dr. Charlotte Roberts,Lotus Qi,Veronica Gray,Nara Daubeney PhD 💡Mapping out strong milestones in your pitch is key to engaging investors. Be authentic and prepared in your pitch. 9 times out of 10 the questions you'll be asked are highly predictable, so find programmes or accelerators that can help you prepare. “Insights, Funding Strategies, and Top Tips for Healthcare and Life Science Commercialisation” Michael Thomas,Kristina Pereckaite, Fred Bassett (FRSA), Filippo Falaschi 💡Investors aren't concerned about start-ups having a formal marketing strategy. However, you do need to show a basic understanding of marketing principles in your deck, as it’s essential for communicating your value prop and telling your story. “Insights, Funding Strategies, and Top Tips for Healthcare and Life Science Commercialisation” Michael Thomas,Kristina Pereckaite, Fred Basset, Filippo Falaschi A huge well done to all who were involved in the #DiscoverySpark pitches this year, it was fantastic to see the variety of start-ups on show 🌟 SmileScaff – Linh TB Nguyen 🌟 RS&RS Scientific LTD – Dr Roghaiyeh (Rugi) Safari 🌟 Pelvity – Rebecca Hyman, Naomi Hyman 🏆 Congratulations to the winner Katy L. a powerful pitch describing how her own experiences have led to her creating her company Ask Joan Want the full run down of the day? Head to Maaria's article: https://lnkd.in/eF5WsHXj #mowbi #events #giant2024 #startups 

At Mowbi, we specialise in bridging the communication gap for life science. Our writing team combines industry specific knowledge and commercial experience to transform your scientific concepts into messaging that resonates with a range of audiences. Our creatives offer fresh ideas to enhance your content. Need a boost to your projects? Find out more about how Mowbi supports enterprises: https://lnkd.in/eYXfrS_8 #mowbi #contentcreation #messaging #lifescience #marketing #comms

On Monday we’re joining Discovery Park at the GIANT Health Event in London, the UK’s foremost NHS innovation festival. Keep an eye on our page to hear our updates! Want to know more about this innovative event? There’s still a few tickets available: https://www.giant.health/ #GIANT2024 #healthcare #NHS #comms #Mowbi

Last weeks Advanced Therapies Integrates was full of interesting fireside chats and panels discussions about the future of cell and gene therapies. Here's a few of our key takeaways 👇 💡“CGT developers need to lean into people with lived experience early in the development of CGTs to harness their knowledge. They might not currently do that because it is a highly emotive area, but patient led organisations have a wealth of resources and are motivated to move the needle” For the people who need them- Nicola Redfern (NJ Redfern Ltd), James Kelly (MEF2C Foundation) 💡 “Digital 5.0 is all about having a human centric approach to digital technologies. If we're to get to manufacturing thousands of batches, we need resilience in our processes. This requires visibility and transparency across the manufacturing process that humans can then interrogate and respond to.” Make Them Better- Stephen Ward (Cell and Gene Therapy Catapult), Rebecca Street (RoslinCT), Katy Newton (Achilles Therapeutics plc), Antoine Espinet (MFX) Edwin Stone (Cellular Origins) Kwok Pang (adthera bio) 💡 “For CGT investment, it's important to clearly define your patient population and have access to them. Not doing this as a company and suffering the negative consequences can have a knock-on effect to the wider industry with regards to investor confidence.” Funding Battles- Jeanette Evans (Cell and Gene Therapy Catapult), Karolina Zapadka, PhD MBA (Parkwalk Advisors), Stefanos Theoharis (OneChain Immunotherapeutics), Abigail Martin (ImmuONE), Sam Goldsmith PhD (Cell and Gene Therapy Catapult) 💡 “When looking at digital technologies. You have to understand how to bring people on board instead of fear mongering with new technologies or processes. We also shouldn't use digital technologies just for the sake of it, and make sure it works with people.” It’s an upskill battle- Ian M. Parnham, PhD (Cell and Gene Therapy Catapult), James Kusena PhD, (MFX), Mustafa Munye (Complement Therapeutics), Saerah Khan (Rentschler Biopharma), Dharmesh Vara (Cytiva), Anji Miller Ph.D CLP RTTP (LifeArc) For a full run down of the day, head to our founder Maaria's article: https://lnkd.in/e35EZX85 Thanks to all of the panellists and to Life Science Integrates for an excellent event! #advancedtherapiesintegrates #cgt #celltherapies #genetherapies #lifescience #events #mowbi

💡Are your revolutionary ideas not quite making the impact you want? When you’re busy doing what you do best, marketing can (and does) take a backseat. That’s where we come in. Mowbi bridge the gap between scientific innovations and engaging communication. We’re founded by scientists who are passionate about transforming your technology into messaging and content that resonates with your audience. Ready to amplify your science? Come have a chat: https://www.mowbi.co.uk/ #mowbi #marketingagency #contentcreation #lifescience

🌟 We’re very excited to spend an evening celebrating the fantastic life science community at the OBN (UK) Ltd awards next week, and honoured to be finalists for the “Best Industry Support” category! If you’re attending, come and say hi! Want to know more about Mowbi? https://www.mowbi.co.uk/ #mowbi #awardseason #finalists #industryaward 

Are you thinking about your marketing goals for 2025? If you are but you don’t know where to start, Scrappy Marketing is here to help. Our guide lays out the marketing essentials to help you start your marketing journey. Download your free copy now for insights on: 🗂️ How to build an effective strategy 💡 Creating content and where to post it 🧱 Building a brand identity 🤖 If and when to utilise AI If you haven't downloaded Scrappy Marketing yet, now's the time! Boost your marketing strategy and digital output for 2025 🚀 https://lnkd.in/ei6NbnT2 #scrappymarketing #mowbi #marketing #2025planning 

💊 What’s been happening in Pharma? With a host of recent pharmaceutical announcements, including ground-breaking collaborations, research updates, and even a Nobel Prize, it's clear that conference season is in full swing. Here are a few of the latest developments 👇 Bicycle Therapeutics presented the first human imaging data at #EANM2024 Congress. Validating MT1-MMP as a novel cancer treatment target and also demonstrating the potential of their Bicycle Radionuclide Conjugates (BRC®) technology for radiopharmaceutical use. Exscientia announced that two discovery programs within their Sanofi collaboration have advanced to lead optimisation phase. Both programs have demonstrated high differentiation in early profiling with potential to produce best-in-class assets. Isomorphic Labs CEO and founder Demis Hassabis has been awarded the 2024 Nobel Prize in Chemistry, alongside John Jumper, for their ground-breaking work creating AlphaFold, an AI program that predicts protein structures. Quotient Therapeutics announced two research collaborations with Pfizer. The companies will analyse somatic mutations that occur in diseased patient tissue to inform the discovery and development of potentially transformative therapies for cardiovascular and renal diseases. Vertex Pharmaceuticals provided updates on multiple kidney disease programs at #ASN Kidney Week Congress, highlighting positive new data for povetacicept, including a 66% reduction in proteinuria at 48 weeks in IgA nephropathy patients and a 62% reduction at 24 weeks in primary membranous nephropathy patients. Do you have some favourite highlights from the pharma world? Join the conversation in the comments! #pharma #roundup #inthenews #mowbi 

📣 We’re so excited to bring you this episode from BioTechX! We had such a great time chatting to an incredible selection of start-ups, and thoroughly enjoyed listening to the diverse range of companies and their communication tips! Thanks again to Rick Schneider Helical, Mael Mertad Deemea, Dr. Lukas Pluska Exazyme, Bettina Duehrkoop juli, Alex Cornean, PhD DataHarmony, Dr. Sebastian Müller Alva Genomics and Pedro Correa de Sampaio Neobe Therapeutics for joining us! Listen now on: Spotify: https://lnkd.in/e86uRKwC Apple: https://lnkd.in/e5WhxV6w YouTube: https://lnkd.in/enfK24zT Web: https://lnkd.in/eunp6-wZ 👋 Enjoyed this episode? Let us know! Subscribe, rate and share the podcast 📷 Want more Pros and Comms? Follow our instagram account for latest episode drops 👉 https://lnkd.in/eq8wUqQv #podcast #prosandcomms #biotechx #startups #communication